"This conference brings together the top leaders in the field of prenatal testing to discuss the latest advances and we are pleased that CellScape's unique approach for isolating fetal blood cells obtained from maternal circulation will be featured," said
CellScape has developed a technology&u=http%3A%2F%2Fwww.cellscapecorp.com%2F%3Fpage_id%3D13">proprietary fetal cell technology which enables it to isolate fetal cells specific to a woman's current pregnancy from a simple maternal blood draw. By isolating these cells, CellScape can access the pure and complete fetal genome and use targeted Chromosomal Microarray Analysis (CMA) to detect prenatally relevant cytogenetic abnormalities. The ClarityTM Prenatal Test will transform prenatal genetic testing by allowing doctors to assess more abnormalities noninvasively and therefore, earlier and more safely.
Dr. Parikh will discuss CellScape's approach for isolating fetal cells and will provide examples of array analysis performed on fetal cells extracted through CellScape's proprietary process. Dr. Parikh will also discuss the importance of chromosomal microarrays to assess copy number variants which can cause clinical syndromes relevant for prenatal testing.
A panel of leading experts in the field of prenatal molecular diagnostics, including several of CellScape's advisors --
About the Clarity™ Prenatal Genetic Test
The Clarity Test uses chromosomal microarray analysis (CMA) of fetal DNA to detect a large but targeted set of known genetic disorders that currently cannot be detected without invasive testing. CMA is already used by many laboratories to analyze DNA from fetal cells collected via invasive procedures because the higher resolution of CMA enables detection of far more abnormalities than karyotyping; CellScape's innovation will make this technology available to women earlier and noninvasively. In addition to all trisomies, the Clarity Test will detect the majority of chromosomal duplication and deletion syndromes (copy number variants, CNVs) identified as prenatally relevant by groups such as the
David Carey/ Tanner Kaufman Lazar Partners Ltd.212 867 1768 firstname.lastname@example.org@lazarpartners.com